These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9639413)

  • 1. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
    Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
    Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
    Passamonti F; Brusamolino E; Lazzarino M; Baraté C; Klersy C; Orlandi E; Canevari A; Castelli G; Merante S; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1011-8. PubMed ID: 11025590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
    Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
    Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.
    Brusamolino E; Salvaneschi L; Canevari A; Bernasconi C
    J Clin Oncol; 1984 Jun; 2(6):558-61. PubMed ID: 6374054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F; Lazzarino M
    Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
    Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
    J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
    Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
    Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pipobroman therapy of polycythemia vera.
    Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
    Blood; 1982 May; 59(5):890-4. PubMed ID: 7074217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.
    Bouscary D; Jondeau K; Viguié F; Zompi S; Fontenay-Roupie M; Quarre MC; Vassilief D; Dreyfus F; Casadevall N
    Leuk Lymphoma; 1999 May; 33(5-6):607-11. PubMed ID: 10342591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
    Najean Y
    Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
    Najean Y; Rain JD
    Blood; 1997 Nov; 90(9):3370-7. PubMed ID: 9345019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
    Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
    Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of polycythaemia with pipobroman].
    Perreau-Boutet MC; Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
    Nouv Presse Med; 1982 Sep; 11(34):2549-53. PubMed ID: 7133977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polycythemia vera as a multiphasic clonal panmyelopathy: diagnostic profile, chronic pathological progression and effect of therapy on the survival of 74 cases].
    Sánchez Fayos J; Prieto E; Román A; Soto de Ozaeta C; Nevado I; Richart A; Chica E; Loscertales J; Calabuig T; Benítez J; Outeiriño J
    Sangre (Barc); 1996 Dec; 41(6):447-57. PubMed ID: 9148422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
    Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
    Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
    Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.